# NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients

> **NCT06845319** · PHASE2 · RECRUITING · sponsor: **Medical University of South Carolina** · enrollment: 43 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06845319
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-20
- **Primary completion:** 2027-10-20
- **Final completion:** 2028-10-20
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06845319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06845319, "NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06845319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*